drugset
drugset / Trial / NCT01019317

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

NCT01019317 ↗

Phase 2 Completed 151 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the combination of fludarabine and cytarabine can help to control Acute Myelogenous Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myeloid Leukemia (CML) in myeloid blast crisis. The safety of this drug combination will also be studied.

Timeline

Start
2009-11
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 500 mg/m2 Intravenous
Subject Fludarabine Small molecule 15 mg/m2 Intravenous

Indications

acute myeloid leukemia chronic myeloid leukemia myelodysplastic syndrome